VSTM

Verastem

4.010

+0.010+0.25%

Pre Market: 4.049 +0.039 +0.98%04:00 06/17 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE4.010/4.000

TODAY RANGE3.850-4.120

VOL78

MARKET CAP352.37M

52 WEEK RANGE3.550-11.25

AVG VOL (3M)2.30M

% TURNOVER1.72%

TURNOVER0

P/E (TTM)-1.6007

% RANGE6.25%

EPS(TTM)-2.5051

P/E(FORWARD)-2.5871

P/B4.308

BVPS0.9309

DIVIDEND--

P/S10.08

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP330.55M

SHARES OUTSTANDING87.87M

NEXT EARNINGS08/05-08/10

FREE FLOAT82.43M

LOT SIZE1

EX-DATE06/01/2023

News

Press Releases

Financial Reports

Profile

Dow Jones·11h ago
Verastem Doses First Patient in Pancreatic Cancer Trial
TipRanks·12h ago
Verastem doses first Patient in TARGET-D 201 Phase 2 trial of VS-7375
PUBT·12h ago
Verastem doses first patient in Phase 2 TARGET-D 201 trial of KRAS G12D inhibitor VS-7375 in metastatic pancreatic cancer
Reuters·12h ago
VERASTEM ONCOLOGY DOSES FIRST PATIENT IN TARGET-D 201 PHASE 2 REGISTRATION-DIRECTED TRIAL OF VS-7375 ORAL KRAS G12D (ON/OFF) INHIBITOR FOR KRAS G12D-MUTATED METASTATIC PANCREATIC CANCER
PUBT·1d ago
Verastem Oncology updates Phase 1/2 TARGET-D 101 data for KRAS G12D inhibitor VS-7375
TipRanks·06/09 15:29
3 Best Stocks to Buy Today, 6/9/2026, According to Top Analysts
TipRanks·06/09 10:50
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), Jazz Pharmaceuticals (JAZZ) and Humana (HUM)
Dow Jones·06/03 20:48
Verastem Oncology Gets FDA Fast Track Designation for Lung Cancer Drug
Reuters·06/03 20:28
BUZZ-Verastem rises after FDA grants fast-track status for cancer drug
TipRanks·06/03 20:23
Verastem up 11% at $4.00 after announcing FDA Fast Track designation for VS-7375
TipRanks·06/03 20:06
Verastem announces FDA Fast Track designation for VS-7375
PUBT·06/03 20:01
Verastem wins FDA fast-track tag for VS-7375 in KRAS G12D-mutated advanced NSCLC after prior therapy
Reuters·06/03 20:01
VERASTEM ONCOLOGY ANNOUNCES U.S. FDA FAST TRACK DESIGNATION FOR VS-7375, AN ORAL AND POTENTIAL BEST-IN-CLASS INVESTIGATIONAL KRAS G12D (ON/OFF) INHIBITOR FOR THE TREATMENT OF KRAS G12D-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Reuters·06/03 20:01
VERASTEM - INITIATES PHASE 2 TARGET-D 202 TRIAL FOR ADVANCED NSCLC
PUBT·05/27 21:44
Verastem files Form 3 initial beneficial ownership statement for director Michael P. Bailey

Same Industry

Name/Symbol

Change%

Price

VSTM

Regeneron Pharmaceuticals

REGN

+0.11%

612.14

GridAI Tech

GRDX

-9.68%

4.760

BNTX

United Therapeutics Corp.

UTHR

+0.10%

545.96

SIGA

Vertex Pharmaceuticals Inc

VRTX

+0.32%

451.88

Moderna

MRNA

+0.54%

49.91

CRL

MEDP

TLPH

ICON plc

ICLR

-2.83%

143.54

CBPO

IQV

MOLECULAR PARTNERS AG

MOLN

-6.33%

3.850

PRAH

Arcturus Therape

ARCT

-2.59%

7.14

Gilead Sciences Inc

GILD

-0.22%

125.59

Incyte Corp

INCY

-6.04%

101.98

APVO

Biospecifics

BSTC

+0.15%

88.53

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.